ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of CPAP on Biomarkers in Patients With OSA (CPAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01138865
Recruitment Status : Unknown
Verified June 2013 by S.K.SHARMA, All India Institute of Medical Sciences, New Delhi.
Recruitment status was:  Recruiting
First Posted : June 8, 2010
Last Update Posted : June 24, 2013
Sponsor:
Information provided by (Responsible Party):
S.K.SHARMA, All India Institute of Medical Sciences, New Delhi

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
CPAP, the standard treatment for Obstructive sleep apnea syndrome (OSAS) that reduces sleep fragmentations and neurocognitive deficit in OSAS may also have a key role in reduction of cardiovascular, mortality risks in the same patients.

Condition or disease Intervention/treatment Phase
Obstructive Sleep Apnea Device: AutoSet Spirit--Wash--Modified-AutoSet Spirit Device: Modified-AutoSet Spirit--Wash-AutoSet Spirit Phase 2 Phase 3

Detailed Description:

Obstructive sleep apnea (OSA) is a condition in which there is collapse of the upper airway during sleep, as a result of which there is a decrease or complete cessation of airflow. This leads to repeated episodes of hypoxia during sleep and sleep fragmentation. It is a highly prevalent though under-recognized clinical problem.There is increasing evidence that inflammation plays important role in development of cardiovascular complications in patients with OSA.

Continuous positive airway pressure (CPAP) is the standard treatment for OSA with significant symptoms.However, it is a costly treatment option and poor compliance is an important limiting factor. CPAP treatment has been shown to improve the daytime somnolence and neurocognitive function in people with OSAS. However, its effect on cardiovascular biomarkers in people with OSAS has not been satisfactorily assessed.

This study aims to assess the effect of CPAP treatment on cardiovascular biomarkers in OSA.


Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Continuous Positive Airway Pressure (CPAP) on Cardiovascular Biomarkers in Patients With Obstructive Sleep Apnea.
Study Start Date : March 2012
Estimated Primary Completion Date : September 2014
Estimated Study Completion Date : March 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
1
Device: AutoSet Spirit--Wash--Modified-AutoSet Spirit 3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
 Device: AutoSet Spirit--Wash--Modified-AutoSet Spirit
3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
Other Name: AutoSet Spirit(TM), ResMed India Ltd.
2
3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
 Device: Modified-AutoSet Spirit--Wash-AutoSet Spirit
3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
Other Name: Modified-AutoSet Spirit(TM), ResMed India Ltd.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Effect of CPAP therapy on blood pressure [ Time Frame: 7 months ]
  2. Effect of CPAP therapy on insulin resistance [ Time Frame: 7months ]
  3. Effect of CPAP therapy on plasma hs-CRP [ Time Frame: 7months ]
  4. Effect of CPAP therapy on lipid profile [ Time Frame: 7months ]
  5. Effect of CPAP therapy on urinary albumin-creatinine ratio [ Time Frame: 7months ]

Secondary Outcome Measures :
  1. Effect of CPAP on anthropometric parameters [ Time Frame: 3 months ]
  2. Effect of CPAP on visceral fat and other imagings [ Time Frame: 3months ]
  3. Effect of CPAP on carotid intima medical thickness [ Time Frame: 3months ]
  4. Effect of CPAP on adipokines and oxidative stress markers [ Time Frame: 3months ]
  5. Effect of CPAP on inflammatory cytokine levels. [ Time Frame: 3months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

The 1st part of the study will include

  1. males and females, aged 30-65 years,
  2. with AHI >5 and excessive daytime sleepiness
  3. naïve to CPAP treatment.
  4. Subjects from first part of the study who have moderately severe OSAS and have never received treatment for OSA,diabetes mellitus and hypertension

Exclusion Criteria:

  1. Hypothyroidism
  2. Chronic renal failure
  3. Chronic liver disease
  4. Chronic lung disease
  5. Known systemic inflammatory diseases (lupus , sarcoidosis and other connective tissue disorders),
  6. Use of drugs that influence urinary protein excretion (eg. steroids, lithium, NSAIDS, ACE inhibitors/Angiotensin Receptor Blockers etc.)
  7. Immune deficiency conditions
  8. Pregnancy
  9. Active menstruation at time of sampling
  10. Macroalbuminuria (aACR>300mg/g),
  11. Patients of coronary artery disease and left ventricular dysfunction
  12. Not on treatment for hypertension, diabetes mellitus or dyslipidemia
  13. Long lasting hypertension or diabetes mellitus (more than 5 years after diagnosis)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01138865


Contacts
Contact: Surendra K Sharma, MD, Ph.D 91-11-26594415 sksharma@aiims.ac.in

Locations
India
All India Institute of Medical Sciences Recruiting
New Delhi, Delhi, India, 110029
Contact: Surendra K Sharma, MD, Ph.D    91-11-26594415    sksharma@aiims.ac.in   
Principal Investigator: Surender K Sharma, MD, Ph.D         
Sub-Investigator: M Irshad, MD         
Sub-Investigator: Vishubhatla Sreenivas, Ph.D         
Sub-Investigator: Ramakrishnan Lakshmy, Ph.D         
Sub-Investigator: Manish Soneja, MD         
Sub-Investigator: Atin Kumar, MD         
Sub-Investigator: Priya Jagia, MD         
Sub-Investigator: Deepak Damodaran, M.B.B.S.         
Sponsors and Collaborators
All India Institute of Medical Sciences, New Delhi
Investigators
Principal Investigator: Surendra K Sharma, MD,Ph.D All India Institute of Medical Sciences, New Delhi
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: S.K.SHARMA, Professor and Haed, All India Institute of Medical Sciences, New Delhi
ClinicalTrials.gov Identifier: NCT01138865     History of Changes
Other Study ID Numbers: SKS/CPAP-OSAS/2009
First Posted: June 8, 2010    Key Record Dates
Last Update Posted: June 24, 2013
Last Verified: June 2013

Keywords provided by S.K.SHARMA, All India Institute of Medical Sciences, New Delhi:
Obstructive sleep apnea
Cytokine levels
Insulin resistance
Hypertension
 Dyslipidemia
Albumin-creatinine ratio
Continuous positive airway pressure (CPAP)

Additional relevant MeSH terms:
Apnea
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
 Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases